These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2228 related items for PubMed ID: 23684925

  • 1. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK, Graab U, Fulda S.
    Cancer Lett; 2013 Sep 01; 337(2):200-9. PubMed ID: 23684925
    [Abstract] [Full Text] [Related]

  • 2. Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma.
    Graab U, Hahn H, Fulda S.
    Oncotarget; 2015 Apr 20; 6(11):8722-35. PubMed ID: 25749378
    [Abstract] [Full Text] [Related]

  • 3. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.
    Opel D, Naumann I, Schneider M, Bertele D, Debatin KM, Fulda S.
    Clin Cancer Res; 2011 May 15; 17(10):3233-47. PubMed ID: 21355080
    [Abstract] [Full Text] [Related]

  • 4. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F.
    Int J Cancer; 2013 Nov 15; 133(9):2089-101. PubMed ID: 23629727
    [Abstract] [Full Text] [Related]

  • 5. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.
    Anticancer Res; 2010 Dec 31; 30(12):4951-8. PubMed ID: 21187475
    [Abstract] [Full Text] [Related]

  • 8. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
    Sheppard KE, Cullinane C, Hannan KM, Wall M, Chan J, Barber F, Foo J, Cameron D, Neilsen A, Ng P, Ellul J, Kleinschmidt M, Kinross KM, Bowtell DD, Christensen JG, Hicks RJ, Johnstone RW, McArthur GA, Hannan RD, Phillips WA, Pearson RB.
    Eur J Cancer; 2013 Dec 31; 49(18):3936-44. PubMed ID: 24011934
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
    Renshaw J, Taylor KR, Bishop R, Valenti M, De Haven Brandon A, Gowan S, Eccles SA, Ruddle RR, Johnson LD, Raynaud FI, Selfe JL, Thway K, Pietsch T, Pearson AD, Shipley J.
    Clin Cancer Res; 2013 Nov 01; 19(21):5940-51. PubMed ID: 23918606
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
    Stehle A, Hugle M, Fulda S.
    Cancer Lett; 2015 Aug 28; 365(1):37-46. PubMed ID: 25917079
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA.
    Cancer Res; 2005 Sep 15; 65(18):8423-32. PubMed ID: 16166321
    [Abstract] [Full Text] [Related]

  • 15. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.
    Bender A, Opel D, Naumann I, Kappler R, Friedman L, von Schweinitz D, Debatin KM, Fulda S.
    Oncogene; 2011 Jan 27; 30(4):494-503. PubMed ID: 20856197
    [Abstract] [Full Text] [Related]

  • 16. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S, Depreeuw J, Coenegrachts L, Hermans E, Lambrechts D, Amant F.
    Gynecol Oncol; 2015 Jul 27; 138(1):165-73. PubMed ID: 25933683
    [Abstract] [Full Text] [Related]

  • 17. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
    López-Fauqued M, Gil R, Grueso J, Hernandez-Losa J, Pujol A, Moliné T, Recio JA.
    Int J Cancer; 2010 Apr 01; 126(7):1549-61. PubMed ID: 19810100
    [Abstract] [Full Text] [Related]

  • 18. Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation.
    Calviño E, Estañ MC, Simón GP, Sancho P, Boyano-Adánez Mdel C, de Blas E, Bréard J, Aller P.
    Biochem Pharmacol; 2011 Dec 01; 82(11):1619-29. PubMed ID: 21889928
    [Abstract] [Full Text] [Related]

  • 19. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
    Thimmaiah KN, Easton J, Huang S, Veverka KA, Germain GS, Harwood FC, Houghton PJ.
    Cancer Res; 2003 Jan 15; 63(2):364-74. PubMed ID: 12543789
    [Abstract] [Full Text] [Related]

  • 20. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.
    Lee JS, Tang SS, Ortiz V, Vo TT, Fruman DA.
    Oncotarget; 2015 Nov 03; 6(34):35202-17. PubMed ID: 26460954
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 112.